U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H14F3N3O2S
Molecular Weight 369.361
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LANSOPRAZOLE

SMILES

CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F

InChI

InChIKey=MJIHNNLFOKEZEW-UHFFFAOYSA-N
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

HIDE SMILES / InChI

Molecular Formula C16H14F3N3O2S
Molecular Weight 369.361
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22950496

Dexlansoprazole (trade names Kapidex, Dexilant) is a proton pump inhibitor (PPI) that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux disease. Dexlansoprazole is used to heal and maintain healing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD). It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often. Dexlansoprazole is supplied for oral administration as a dual delayed-release formulation in capsules and orally disintegrating tablets. The capsules and tablets contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles. The most significant adverse reactions (≥2%) reported in clinical trials were diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PREVACID

Approved Use

Use •treats frequent heartburn (occurs 2 or more days a week) •not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect

Launch Date

1.0306656E12
Primary
PREVACID

Approved Use

Use •treats frequent heartburn (occurs 2 or more days a week) •not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect

Launch Date

1.0306656E12
Primary
PREVACID

Approved Use

Use •treats frequent heartburn (occurs 2 or more days a week) •not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect

Launch Date

1.0306656E12
Primary
DEXILANT

Approved Use

DEXILANT is a proton pump inhibitor (PPI) indicated for: •Healing of all grades of erosive esophagitis (EE). (1.1) •Maintaining healing of EE and relief of heartburn. (1.2) •Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). (1.3) 1.1 Healing of Erosive Esophagitis DEXILANT is indicated for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis DEXILANT is indicated to maintain healing of EE and relief of heartburn for up to six months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Launch Date

1.23327362E12
Curative
DEXILANT

Approved Use

DEXILANT is a proton pump inhibitor (PPI) indicated for: •Healing of all grades of erosive esophagitis (EE). (1.1) •Maintaining healing of EE and relief of heartburn. (1.2) •Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). (1.3) 1.1 Healing of Erosive Esophagitis DEXILANT is indicated for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis DEXILANT is indicated to maintain healing of EE and relief of heartburn for up to six months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Launch Date

1.23327362E12
Primary
PREVACID

Approved Use

INDICATIONS AND USAGE. Short-Term Treatment of Active Duodenal Ulcer PREVACID is indicated for short-term treatment (up to 4 weeks) for healing and symptom relief of active duodenal ulcer. H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence. Triple Therapy: PREVACID/amoxicillin/clarithromycin. PREVACID in combination with amoxicillin plus clarithromycin as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Dual Therapy: PREVACID/amoxicillin. PREVACID in combination with amoxicillin as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Maintenance of Healed Duodenal Ulcers PREVACID is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months. Short-Term Treatment of Active Benign Gastric Ulcer PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer Healing of NSAID-Associated Gastric Ulcer PREVACID IS INDICATED FOR THE TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS WHO CONTINUE NSAID USE. CONTROLLED STUDIES DID NOT EXTEND BEYOND 8 WEEKS. Risk Reduction of NSAID-Associated Gastric Ulcer PREVACID is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks. Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD PREVACID is indicated for the treatment of heartburn and other symptoms associated with GERD. Short-Term Treatment of Erosive Esophagitis PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with PREVACID for 8 weeks (5-10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8-week course of PREVACID may be considered. Maintenance of Healing of Erosive Esophagitis PREVACID is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months. Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome PREVACID is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

Launch Date

1.03057922E12
Primary
PREVACID

Approved Use

INDICATIONS AND USAGE. Short-Term Treatment of Active Duodenal Ulcer PREVACID is indicated for short-term treatment (up to 4 weeks) for healing and symptom relief of active duodenal ulcer. H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence. Triple Therapy: PREVACID/amoxicillin/clarithromycin. PREVACID in combination with amoxicillin plus clarithromycin as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Dual Therapy: PREVACID/amoxicillin. PREVACID in combination with amoxicillin as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Maintenance of Healed Duodenal Ulcers PREVACID is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months. Short-Term Treatment of Active Benign Gastric Ulcer PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer Healing of NSAID-Associated Gastric Ulcer PREVACID IS INDICATED FOR THE TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS WHO CONTINUE NSAID USE. CONTROLLED STUDIES DID NOT EXTEND BEYOND 8 WEEKS. Risk Reduction of NSAID-Associated Gastric Ulcer PREVACID is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks. Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD PREVACID is indicated for the treatment of heartburn and other symptoms associated with GERD. Short-Term Treatment of Erosive Esophagitis PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with PREVACID for 8 weeks (5-10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8-week course of PREVACID may be considered. Maintenance of Healing of Erosive Esophagitis PREVACID is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months. Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome PREVACID is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

Launch Date

1.03057922E12
Primary
PREVACID

Approved Use

INDICATIONS AND USAGE. Short-Term Treatment of Active Duodenal Ulcer PREVACID is indicated for short-term treatment (up to 4 weeks) for healing and symptom relief of active duodenal ulcer. H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence. Triple Therapy: PREVACID/amoxicillin/clarithromycin. PREVACID in combination with amoxicillin plus clarithromycin as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Dual Therapy: PREVACID/amoxicillin. PREVACID in combination with amoxicillin as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Maintenance of Healed Duodenal Ulcers PREVACID is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months. Short-Term Treatment of Active Benign Gastric Ulcer PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer Healing of NSAID-Associated Gastric Ulcer PREVACID IS INDICATED FOR THE TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS WHO CONTINUE NSAID USE. CONTROLLED STUDIES DID NOT EXTEND BEYOND 8 WEEKS. Risk Reduction of NSAID-Associated Gastric Ulcer PREVACID is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks. Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD PREVACID is indicated for the treatment of heartburn and other symptoms associated with GERD. Short-Term Treatment of Erosive Esophagitis PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with PREVACID for 8 weeks (5-10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8-week course of PREVACID may be considered. Maintenance of Healing of Erosive Esophagitis PREVACID is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months. Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome PREVACID is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

Launch Date

1.03057922E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1705 ng/mL
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1136 ng/mL
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex:
food status:
691 ng/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex:
food status:
16.1 (ng/mL)/mg
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
33.5 (ng/mL)/mg
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
37.3 (ng/mL)/mg
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
1005 ng/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
559 ng/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
964 ng/mL
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
658 ng/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1397 ng/mL
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3192 ng × h/mL
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
143.2 (ng*h/mL)/mg
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
55.5 (ng*h/mL)/mg
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
87.6 (ng*h/mL)/mg
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
2149 ng*h/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
2628 ng*h/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
3330 ng*h/mL
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
128 (ng*h/mL)/mg
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
62 (ng*h/mL)/mg
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
96 (ng*h/mL)/mg
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
1914 ng*h/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
2892 ng*h/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
3747 ng*h/mL
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
3275 ng × h/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
6529 ng × h/mL
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.3 h
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.59 h
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex:
food status:
1.66 h
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex:
food status:
Doses

Doses

DosePopulationAdverse events​
30 mg 2 times / day multiple, intravenous
Dose: 30 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
healthy, 18-29 years
n = 18
Health Status: healthy
Age Group: 18-29 years
Sex: M+F
Population Size: 18
Sources:
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
healthy, 18-29 years
n = 8
Health Status: healthy
Age Group: 18-29 years
Sex: M+F
Population Size: 8
Sources:
300 mg single, oral
Highest studied dose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources:
healthy, 35 years (range: 18 - 50 years)
n = 36
Health Status: healthy
Age Group: 35 years (range: 18 - 50 years)
Sex: M+F
Population Size: 36
Sources:
60 mg 1 times / day steady, oral
Recommended
unhealthy, 48 years (range: 18-90 years)
n = 2218
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 2218
Sources:
Disc. AE: Diarrhea...
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources: Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 2218
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 2218
Sources: Page: p. 35
Disc. AE: Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (0.5%)
Sources: Page: p. 35
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources: Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 455
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 455
Sources: Page: p. 35
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (0.2%)
Sources: Page: p. 35
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources: Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 1754
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 1754
Sources: Page: p. 35
Disc. AE: Diarrhea, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Diarrhea (0.7%)
Abdominal pain (0.6%)
Sources: Page: p. 35
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources: Page: p. 36
unhealthy, adult
n = 2311
Health Status: unhealthy
Age Group: adult
Population Size: 2311
Sources: Page: p. 36
Disc. AE: Dyspepsia, Eructation...
AEs leading to
discontinuation/dose reduction:
Dyspepsia (3 patients)
Eructation (2 patients)
Nausea (6 patients)
Vomiting (6 patients)
Erosive esophagitis (1 patient)
Sources: Page: p. 36
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources: Page: p. 36
unhealthy, adult
n = 2142
Health Status: unhealthy
Age Group: adult
Population Size: 2142
Sources: Page: p. 36
Disc. AE: Dyspepsia, Eructation...
AEs leading to
discontinuation/dose reduction:
Dyspepsia (1 patient)
Eructation (1 patient)
Nausea (9 patients)
Vomiting (6 patients)
Sources: Page: p. 36
60 mg 2 times / day steady, oral
Overdose
Dose: 60 mg, 2 times / day
Route: oral
Route: steady
Dose: 60 mg, 2 times / day
Sources:
unhealthy
Other AEs: Hypertension...
AEs

AEs

AESignificanceDosePopulation
Diarrhea 0.7%
Disc. AE
60 mg 1 times / day steady, oral
Recommended
unhealthy, 48 years (range: 18-90 years)
n = 2218
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 2218
Sources:
Abdominal pain 0.5%
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources: Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 2218
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 2218
Sources: Page: p. 35
Diarrhea 0.2%
Disc. AE
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources: Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 455
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 455
Sources: Page: p. 35
Abdominal pain 0.6%
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources: Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 1754
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 1754
Sources: Page: p. 35
Diarrhea 0.7%
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources: Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 1754
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 1754
Sources: Page: p. 35
Erosive esophagitis 1 patient
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources: Page: p. 36
unhealthy, adult
n = 2311
Health Status: unhealthy
Age Group: adult
Population Size: 2311
Sources: Page: p. 36
Eructation 2 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources: Page: p. 36
unhealthy, adult
n = 2311
Health Status: unhealthy
Age Group: adult
Population Size: 2311
Sources: Page: p. 36
Dyspepsia 3 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources: Page: p. 36
unhealthy, adult
n = 2311
Health Status: unhealthy
Age Group: adult
Population Size: 2311
Sources: Page: p. 36
Nausea 6 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources: Page: p. 36
unhealthy, adult
n = 2311
Health Status: unhealthy
Age Group: adult
Population Size: 2311
Sources: Page: p. 36
Vomiting 6 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources: Page: p. 36
unhealthy, adult
n = 2311
Health Status: unhealthy
Age Group: adult
Population Size: 2311
Sources: Page: p. 36
Dyspepsia 1 patient
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources: Page: p. 36
unhealthy, adult
n = 2142
Health Status: unhealthy
Age Group: adult
Population Size: 2142
Sources: Page: p. 36
Eructation 1 patient
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources: Page: p. 36
unhealthy, adult
n = 2142
Health Status: unhealthy
Age Group: adult
Population Size: 2142
Sources: Page: p. 36
Vomiting 6 patients
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources: Page: p. 36
unhealthy, adult
n = 2142
Health Status: unhealthy
Age Group: adult
Population Size: 2142
Sources: Page: p. 36
Nausea 9 patients
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources: Page: p. 36
unhealthy, adult
n = 2142
Health Status: unhealthy
Age Group: adult
Population Size: 2142
Sources: Page: p. 36
Hypertension serious
60 mg 2 times / day steady, oral
Overdose
Dose: 60 mg, 2 times / day
Route: oral
Route: steady
Dose: 60 mg, 2 times / day
Sources:
unhealthy
Overview

Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
no (co-administration study)
Comment: in vivo studies showed that DEXILANT did not have an impact on the pharmacokinetics of coadministered theophylline (CYP1A2 substrate)
Page: 11.0
unlikely
no (co-administration study)
Comment: in vivo studies showed that DEXILANT did not have an impact on the pharmacokinetics of coadministered phenytoin (CYP2C9 substrate)
Page: 11.0
weak
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (pharmacogenomic study)
Comment: mean dexlansoprazole Cmax and AUC values were up to 2 times higher in intermediate compared to extensive metabolizers; in poor metabolizers, mean Cmax was up to 4 times higher and mean AUC was up to 12 times higher compared to extensive metabolizers
Page: 10,12
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Advantage of expressing the variations in some digestive parameters as a function of gastric emptying instead of time.
2001
Resolution of Ménétrier's disease after Helicobacter pylori eradicating therapy.
2001
A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
2001
Efficacy of Helicobacter pylori eradication therapies: a single centre observational study.
2001
[The effectiveness of 7-day combined Helicobacter eradication therapy in patients with peptic ulcer and chronic gastritis].
2001
Drug interaction: omeprazole and phenprocoumon.
2001
Effects of pirenzepine, omeprazole, lansoprazole, and rabeprazole on human neutrophil functions.
2001 Apr
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
2001 Apr
Intragastric acidification reduces the occurrence of false-negative urea breath test results in patients taking a proton pump inhibitor.
2001 Apr
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
2001 Apr 15
Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia.
2001 Aug
Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen.
2001 Aug
Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in Brazilian patients with peptic ulcer.
2001 Jan-Feb
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
2001 Jul
Pseudomembranous colitis without diarrhoea following Helicobacter pylori eradication therapy.
2001 Jul
Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
2001 Jul
Quadruple therapy for symptomatic spontaneous duodenal ulcer disease.
2001 Jul
Follow-up of Helicobacter pylori status by using 13C-urea breath test in nonulcer dyspeptic patients after eradication therapy.
2001 Jun
[Bifid median nerve in the carpal tunnel: integrated imaging].
2001 Jun
CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
2001 Jun
Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori.
2001 Jun
Helicobacter pylori and early duodenal ulcer status post-treatment: a review.
2001 Jun
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
2001 Jun
Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
2001 Jun
Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study.
2001 Jun
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
2001 Jun
Proton pump inhibitors: a study of GPs' prescribing.
2001 Jun
Effect of Helicobacter pylori eradication on cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) expression during gastric adaptation to aspirin (ASA) in humans.
2001 Jun 1
Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.
2001 Jun 2
Gastroprotective effect of aparisthman, a diterpene isolated from Aparisthmium cordatum, on experimental gastric ulcer models in rats and mice.
2001 Mar
Acetaldehyde production and other ADH-related characteristics of aerobic bacteria isolated from hypochlorhydric human stomach.
2001 Mar
Electrochemical studies and differential pulse polarographic analysis of lansoprazole in pharmaceuticals.
2001 Mar
[Gynecomastia associated with the simultaneous use of cisapride and lansoprazole].
2001 Mar 24
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
2001 Mar 9
Lansoprazole triple therapy for Turkish children with Helicobacter pylori infections.
2001 May
Proton pump inhibitors and their drug interactions: an evidence-based approach.
2001 May
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
2001 May
Impact of different therapeutic regimens on the outcome of patients with Crohn's disease of the upper gastrointestinal tract.
2001 May
Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases.
2001 May
Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg.
2001 May
Proton pump inhibitor resistance in the treatment of laryngopharyngeal reflux.
2001 Oct
Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B(12) deficiency?
2001 Sep
Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients.
2001 Sep
Review article: tackling the "dyspeptic problem".
2001 Sep
Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis.
2001 Sep
Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
2001 Sep
Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?
2001 Sep
Clinical and ethical concerns about switching patient treatment to "therapeutically interchangeable" medications.
2001 Sep 24
Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice.
2001 Sep 24
Gastroesophageal reflux disease presenting as xerophthalmia.
2001 Sep-Oct
Patents

Sample Use Guides

Duodenal Ulcers: 15 mg (7.5mg Levolansoprazole) Once daily for 4 weeks Gastroesophageal Reflux: 30 mg (15mg Levolansoprazole) Once daily for up to 8 weeks
Route of Administration: Oral
The activity of (H+/K+)-ATPase was measured as follows: the reaction mixture contained, in a total volume of 1 mL, 70 mM Tris-HCl buffer (pH 6.8), 5 mM MgCl 2 and 20 mkg/mL membrane protein with various concentrations of Levolansoprazole in the presence or absence of 10 mM KC1 and 10mkM valinomycin. The assay was carried out at 37 °. After a preincubation period of 1 hr, the reaction was initiated by adding 2 mM ATP and the preparation was incubated for 20 min. The reaction was stopped by adding 1 mL of 12% trichloroacetic acid. Inorganic phosphate produced by ATP hydrolysis was determined according to the method of Fiske and Subbarow
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:06:27 UTC 2023
Edited
by admin
on Wed Jul 05 23:06:27 UTC 2023
Record UNII
0K5C5T2QPG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LANSOPRAZOLE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
LANSOPRAZOLE [MI]
Common Name English
LANZOR
Brand Name English
AG-1749
Code English
LANSOPRAZOLE [ORANGE BOOK]
Common Name English
2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
Systematic Name English
LANSOPRAZOLE COMPONENT OF PREVPAC
Common Name English
LANSOPRAZOLE [USP MONOGRAPH]
Common Name English
PREVACID
Brand Name English
PREVPAC COMPONENT LANSOPRAZOLE
Brand Name English
TAKEPRON
Brand Name English
2-(((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE
Systematic Name English
Lansoprazole [WHO-DD]
Common Name English
A-65006
Code English
LANSOPRAZOLE [EP MONOGRAPH]
Common Name English
LANZOPRAZOLE
Common Name English
AGOPTON
Brand Name English
lansoprazole [INN]
Common Name English
(±)-LANSOPRAZOLE
Common Name English
PREVONCO
Brand Name English
NSC-758638
Code English
LANSOX
Brand Name English
LANSOPRAZOLE [USP-RS]
Common Name English
LIMPIDEX
Brand Name English
LANSOPRAZOLE [HSDB]
Common Name English
LANSOPRAZOLE [JAN]
Common Name English
LANSOPRAZOLE [MART.]
Common Name English
1H-BENZIMIDAZOLE, 2-(((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-
Systematic Name English
OGAST
Brand Name English
ZOTON
Brand Name English
OGASTORO
Brand Name English
LANSOPRAZOLE [VANDF]
Common Name English
LANSOPRAZOLE [USAN]
Common Name English
Classification Tree Code System Code
WHO-ATC A02BC03
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
WHO-VATC QA02BD07
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
LIVERTOX NBK548452
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
WHO-VATC QA02BD03
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
WHO-ATC A02BD03
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
WHO-VATC QA02BD02
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
WHO-ATC A02BD02
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
WHO-ATC A02BD10
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
WHO-ATC A02BD07
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
NCI_THESAURUS C29723
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
WHO-VATC QA02BC03
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
FDA ORPHAN DRUG 446014
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
WHO-ATC A02BC53
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
NDF-RT N0000000147
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
NDF-RT N0000175525
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
FDA ORPHAN DRUG 264508
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
WHO-ATC A02BD09
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
Code System Code Type Description
MERCK INDEX
M6683
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY Merck Index
DAILYMED
0K5C5T2QPG
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
SMS_ID
100000089867
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
RXCUI
17128
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY RxNorm
RS_ITEM_NUM
1356916
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
NDF-RT
N0000009724
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY Inhibition Gastric Acid Secretion [PE]
PUBCHEM
3883
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
DRUG CENTRAL
1547
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
CAS
103577-45-3
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
INN
6397
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
IUPHAR
7208
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
DRUG BANK
DB00448
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
NCI_THESAURUS
C29150
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
WIKIPEDIA
LANSOPRAZOLE
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
MESH
C058687
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
NSC
758638
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
HSDB
7204
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
LACTMED
Lansoprazole
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
EPA CompTox
DTXSID4023200
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
FDA UNII
0K5C5T2QPG
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
EVMPD
SUB08403MIG
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
ChEMBL
CHEMBL480
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
USAN
AA-78
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
CHEBI
6375
Created by admin on Wed Jul 05 23:06:27 UTC 2023 , Edited by admin on Wed Jul 05 23:06:27 UTC 2023
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
DEGRADENT -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
DEGRADENT -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
METABOLIC ENZYME -> INDUCER
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
METABOLITE ACTIVE -> PRODRUG
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
These metabolites have very little or no antisecretory activity.
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC With Hepatic impairment
PHARMACOKINETIC
Elderly
PHARMACOKINETIC